Torun Acar Banu, Duman Erkan, Simsek Saban
Haydarpasa Numune Education and Research Hospital, Ophthalmology Clinic, Kavakli sok. Menekse ap. No.22K.7 D.14 Caddebostan, Istanbul, Turkey.
Tuzla Government Hospital, Ophthalmology Clinic, Istanbul, Turkey.
BMC Ophthalmol. 2016 Nov 29;16(1):208. doi: 10.1186/s12886-016-0389-8.
To evaluate the clinical outcomes after the implantation of a new trifocal diffractive intraocular lens (IOL) combined with Enhanced depth of focus (EDOF) technology.
The study enrolled 80 eyes of 40 patients who underwent cataract surgery with bilateral implantation of a diffractive trifocal IOL (Reviol Tri-ED) designed with a combination of enhanced depth of focus. Mean age was 52.09 ± 11.32 years (range from 45 to 70 years). Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), corrected intermediate visual acuity (CIVA), uncorrected near visual acuity (UNVA), corrected near visual acuity (CNVA), keratometry (K), and manifest refraction spherical equivalent (MRSE) were evaluated pre- and postoperatively. The contrast sensitivity, defocus curves, and a questionnaire evaluating individual satisfaction were also estimated.
There was a significant improvement in UDVA, CDVA, UNVA, CNVA, CIVA postoperatively. The defocus curve confirmed good visual acuity also in the intermediate distance. The postoperative MRSE was ranged from -0.75 to 0.75 diopters. Contrast sensitivity also significantly improved postoperatively. The patient satisfaction was high.
The new trifocal EDOF IOL provides visual improvement for far, intermediate, and near distances with a high level of visual quality and patient satisfaction.
评估植入一种结合了增强景深(EDOF)技术的新型三焦点衍射人工晶状体(IOL)后的临床效果。
该研究纳入了40例患者的80只眼睛,这些患者接受了白内障手术,并双侧植入了一种设计为结合增强景深的衍射三焦点IOL(Reviol Tri-ED)。平均年龄为52.09±11.32岁(范围为45至70岁)。术前和术后评估未矫正远视力(UDVA)、矫正远视力(CDVA)、未矫正中视力(UIVA)、矫正中视力(CIVA)、未矫正近视力(UNVA)、矫正近视力(CNVA)、角膜曲率(K)和明显屈光球镜当量(MRSE)。还评估了对比敏感度、散焦曲线以及一份评估个体满意度的问卷。
术后UDVA、CDVA、UNVA、CNVA、CIVA有显著改善。散焦曲线证实中距离视力也良好。术后MRSE范围为-0.75至0.75屈光度。术后对比敏感度也显著提高。患者满意度较高。
新型三焦点EDOF IOL在远、中、近距离均能改善视力,具有较高的视觉质量和患者满意度。